Ares Genetics Revenue and Competitors

Ares Genetics GmbH is a wholly owned subsidiary of Curetis GmbH, a developer of next-generation molecular diagnostic solutions for infectious diseases. Ares Genetics was established in March 2017 and is located at the Vienna Biocenter, Austria. The Company builds on GEAR Genetic Antibiotic Resistance and Susceptibility Database: the most comprehensive collection of pathogen genomes and antibiotic resistance profiles, which was originally developed and compiled by the Ares Genetics management team at Siemens and acquired by the Curetis Group in late 2016. With a strong core team of bioinformatics experts and life science project managers and supported by Curetis' IVD R&D team, the company leverages its proprietary technology platform within the Curetis Group as well as in collaborative projects with partners in industry and academia. Based on the ARES Technology platform that combines GEAR with proprietary data analysis & interpretation solutions, Ares Genetics develops and commercializes novel approaches to improve the rapid detection of pathogens and their resistance to antibiotics in patients with microbial infections as well as tools to accelerate antibiotic research. Ares Genetics offers a comprehensive BioIT, NGS service & antibiotic resistance testing infrastructure and network as well as tailored solutions for next-generation infectious disease diagnostics & therapeutics to partners in academia, public health and industry. Imprint: https://www.ares-genetics.com/imprint